Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids.
Giulio EvangelistiFabio BarraUmberto PerroneNadine Di DonatoStefano BoglioloMarcello CeccaroniSimone FerreroPublished in: Expert opinion on drug metabolism & toxicology (2022)
The most recent therapeutic strategies for uterine fibroids are represented by gonadotropin-releasing hormone antagonists (GnRH-ants; elagolix and relugolix) and selective progesterone receptor modulators (SPRM; ulipristal acetate). After early promising results, studies on innovative drugs, such as linzagolix (GnRH-ant) and vilaprisan (SPRM) are demanding. In the near future, a deeper knowledge of biological mechanisms at the basis of the genesis and growth of uterine fibroids could pave the way for the development of innovative targeted therapies.